Denosumab Strategy for Liver Cancer With Bone Metastases

NCT07537972 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Bone Metastases

Interventions

DRUG: Denosumab
DRUG: Sintilimab
OTHER: Delayed/Rescue Bone-Modifying Strategy

Sponsor

Tongji Hospital